2. Abdul-Kareem M, et al. Intravenous iron saccharate in hemodialysis patients receiving r-HuEPO. Saudi Journal of Kidney Diseases and Transplantation 1994; 5

3. Al-Momen AK, et al. Intravenous iron saccharate in hemodialysis patients receiving r-HuEPO. Saudi Journal of Kidney Diseases and Transplantation 1994; 5(2): 168-172

4. Al-Momen AK, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. European Journal of Obstetrics and Gynecology and Reproductive Biology 1996; 69: 121-124

5. Al-Momen AK, et al. Enhancement of rHuEPO effect by iron (lll) – hydroxide sucrose complex in hemodialysis patients. Clinical study report. Data on file.

6. Bayoumeu F, et al. Antipublic antibodies and pregnancy: use of iron sucrose in autologous blood donation with cryopreservation. Annals of French Anaesthesiology and Reanimation 2002; 21(1): 27-31

7. Bayoumeu F, et al. Itron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. American Journal of Obstetricy and Gynecpology 2002; 186: 518-522

8. Beris P, et al. Perisurgical intravenous iron therapy. Transfusion Alternatives in Transfusion Medicine 1999; 1(4): 35-38

9. Beris P, et al. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. A prospective study. Vox Sanguinis 1993; 65: 212-218

10. Bernière J, et al. Intravenous iron therapy for correction of post-operative anemia following spinal surgery in children. Revue de Chirurgie Orthopèdique 1998; 84: 319-322

11. Beshara S, et al. Kinetic analysis of 52Fe-labeled iron (lll) hydroxide sucrose complex following bolus administration using positron emission tomography. British Journal of Haematology 1999; 104: 288-295

12. Beshara S, et al. Pharmacokinetics and red cell utilisation of iron (III)-hydroxide sucrose complex in anaemic patients: a study using positron emission tomography. British Journal of Haematology 1999; 104:296-302.

13. Breymann C, et al. Effectiveness of recombinant erythropoietin and iron sucrose versus iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis. European Journal of Clinical Investigation 2000; 30: 154-161

14. Breymann C, et al. Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy. American Journal of Obstetrics and Gynecology 2001, 184. 662-6670

15. Breymann C, et al. Recombinant human erythropoietin and parenteral iron in the treatment of pregnancy anemia: a pilot study. Journal of Perinatal Medicine 1995; 23: 89-98

16. Breymann C, et al. Use of recombinant human erythropoietin in combination with parenteral iron in the treatment of postpartum anemia. European Journal of Clinical Investigation 1996; 26: 123-130

17. Breymann C, et al. Modern therapy concepts of severe anemia in pregnancy and postpartum. In: Prevention and management of anemia in pregnancy and postpartum haemorrhage. Schellenberg Druck AG, Zurich, Switzerland: 107-121

18. Chandler G, et al. Intravenous iron sucrose: establishing a safe dose. American Journal of Kidney Diseases 2001; 38(5): 988-991

19. Charytan C, et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. American Journal of Kidney Diseases 2001; 37(2): 300-307

20. Danielson BG, et al. Pharmacokinetics of iron (lll) hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittel- Forschung Drug Research 1996; 46(l): 615-621

21. Descombes E, et al. Improved response to erythropoietin therapy with long-term continuous iron supplementation. Nephron 2000; 84: 196-197

22. De Pree C, et al. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation in elective surgery with large blood needs (> or = 5 units): a randomized study. Transfusion 1997; 37: 708-714

23. DomrongKitchaiporn, et al. Indices of iron status in continuous ambulatory peritoneal dialysis patients. American Journal of Kidney Diseases 1999; 34(1): 29-35

24. Eschbach JW, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. New England Journal of Medicine 1987; 316: 73-78

25. Fletcher LM, et al. Effects of iron loading on free radical scavenging enzymes on lipid peroxidation in rat liver. Gastroenterology 1989; 97: 1011

26. Gasché C, et al. Sequential treatment of anaemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion 1999; 60: 262-267

27. Gasché C, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. Annals of Internal Medicine 1997; 126 (10): 782-787

28. Gasché C. et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. The American Journal of Gastroenterology 2001, 96(8): 2382-2387

29. Geisser P, et al. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittel-Forschung/Drug Research 1992; 42(ll):1439-1452

30. Gravier A, et al. Comment éviter les transfusions dans le post-partum: intérêt dúne supplémentation martiale par voie intraveineuse. Journal of Gynecology Obstetrics and Biology Reproduction

31. Höchli P, et al. Repeated continuous administration of low doses of intravenous iron in anemic patients with active rheumatoid arthritis. European Journal of Haematology 1993; 51: 54-55

32. Hörl WH. Should we still use iron dextran in hemodialysis patients?. American Journal of Kidney Diseases 2001; 37(4): 859-861

33. Huntington Life Sciences. Toxicity of rats by repeated (once weekly) intravenous infusion for 13 weeks. Report 1995a, Ref Nº VFR 3/951491

34. Huntington Life Sciences. Toxicity of dogs by repeated (once weekly) intravenous infusion for 13 weeks. Report 1995b, Ref Nº VFR 5/951735

35. Huntington Life Sciences. Ferrum Hausman I.V. metaphase chromosome analysis of human lymphocytes cultured in vitro. Report 1995c, Ref Nº VFR 4/950317

36. Huntington Life Sciences. Bacterial mutation assay. Report 1997a, Ref Nº VFR 012/1211

37. Huntington Life Sciences. Mamalian cell mutation assay. Report 1997b, Ref Nº VFR 014/971264

38. Huntington Life Sciences. Mouse micronucleus test. Report 1997c, Ref Nº VFR 013/1243

39. Hussain R, et al. Experience of iron saccharate supplementation in hemodialysis patients treated with erythropoietin. Nephrology 1998; 4: 105-108

40. Ja-Lian L, et al. Short-term small-dose intravenous iron trial to detect functional iron deficiency in dialysis patients. American Journal of Nephrology 2001; 21:91-97

41. Kaltwasser JP, et al. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. Journal of Rheumatology 2001; 28: 2430-2436

42. Lebrecht A, et al. Postpartum anemia: intravenous iron supplementation renders therapy with rHuEPO redundant. Geburts und Frauenheilk 1995; 55:167-170

43. Macaulay D, et al. A peritoneal dialysis satellite unit’s experience with intravenous Venofer infusions. 5th European Peritoneal Dialysis Meeting, Brussels , Belgium 4-7 May 2002; 22(1)

44. Macdougall IC, et al. Detection of functional iron deficiency during erythropoietin treatment. A new approach. British Medical Journal 1992; 304: 225-226

45. Macdougall IC, et al. Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Current Opinion in Nephrology and Hypertension 1994; 3: 620-625

46. Macdougall IC, et al. Characterization of iron availability fron three different i.v. iron preparations in dialysis patients. Internal Report 1998, Data on file

47. Macdougall IC, et al. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. American Journal of Kidney Diseases 1999; 34(suppl 4): S40-S48

48. Macdougall IC. Intravenous administration of iron in epoetin-treated haemodialysis patients-which drugs, which regimen?. Nephrology Dialysis and Transplantation 2000; 15: 1743-1745

49. Martini A, et al. Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet 1994; 344: 1052-1054

50. Mercuriali F, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 1993; 33: 55-60

51. Mercuriali F, et al. Use of recombinant human erythropoietin to assist autologous blood donation by anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Transfusion 1994; 34: 501-506

52. Mercuriali F, et al. Randomized, double-blind, placebo-controlled, dose-finding study with recombinant human erythropoietin to facilitate autologous blood donation in low hematocrit patients undergoing total hip replacement. British Journal of Anaesthesia 1995; 74: 63

53. Mercuriali F, et al. Comparison between intravenous and subcutaneous recombinant human erythropoietin (epoetin alpha) administration in perisurgical autologous blood donation in anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Vox Sanguinis 1997; 72:93-100

54. Mercuriali F, et al. Iron administration to optimize the effect of r-HuEPO in the surgical setting. Erythropoiesis: New dimensions in the treatment of anaemia 1995; Vol 6:67-76

55. Messer J, et al. Erythropoietin and iron in the anemia of prematurity. TATM 1999; 1:15-17

56. Meyer MP, et al. A comparison between oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. Journal of Pediatrics. 1996; 129: 258-263

57. Meyer MP, et al. Recombinant human erythropoietin in the treatment of anemia of prematurity: results of a double blind, placebo-controlled study. Pediatrics 1994; 93: 918-923

58. Mollison LP, et al. Blood Transfusion. Seminars in Hematology 1998; 36 (suppl 7): 48-58

59. Montecucco C, et al. Iron status inStill’s disease. The Lancet 1994; 345(7): 59

60. Morgan H, et al. Maintenance intravenous iron therapy in pediatric hemodialysis patients. Pediatric Nephrology 2001; 16: 779-783

61. Müller A, et al. Classification and properties of iron preparations. Arzneimittel-Forschung/Drug Research 1974; 24(6):880-883

62. Nyvad O, et al. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. The Lancet 1994; 344(5): 1305-1306

63. Perewusnyk G, et al. Parenteral iron therapy in obstetrics: 8 years experience with iron-sucrose complex. British Journal of Nutrition 2002; 88: 3-10

64. Richardson D, et al. Intravenous iron for CAPD populations: proactive or reactive strategies?. Nephrology Dialysis and Transplantation 2001; 16: 115-119

65. Richardson D, et al. Intervention thresholds and ceilings can determine the haemoglobin outcome distribution in a haemodialysis population. Nephrology Dialysis and Transplantation 2000; 15: 2007-2013

66. Richardson D, et al. Optimizing erythropoietin therapy in hemodialysis patients. American Journal of Kidney Diseases 2001; 38(1): 109-117

67. Rohling RG, et al. Intravenous versus oral iron supplementation for preoperative stimulation of hemoglobin synthesis using recombinant human erythropoietin. Journal of Hematotherapy & Stem Cell Research 2000; 9: 497-500

68. Silverberg DS, et al. Intravenous iron for the treatment of pre-dialysis anemia. Kidney International 1999; 55(69): S79-S85

69. Silverberg DS, et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72: 413-417

70. Silverberg DS, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. American Journal of Kidney Diseases 1996; 27(2): 234-238

71. Silverberg DS, et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clinical Nephrology 2001; 55(3): 212-219

72. Silverberg DS, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant, congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. Journal of the American College of Cardiology 2000; 35(7): 1737-1744

73. Silverberg DS, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. Journal of the American College of Cardiology 2001; 37(7): 1775-1780

74. Skikne BS, et al. Effect of enhanced erythropoiesis on iron absortion. Journal of Laboratory and Clinical Medicine. 1992; 120: 746-751

75. Stoves J, et al. A randomized study of oral versus intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrology Dialysis and Transplantation 2001; 16(5): 967-974

76. Sunder-Plassman G, et al. Iron metabolism and iron substitution during erythropoietin therapy. Clinical Investigation 1994; 72: S11-S15

77. Sunder-Plassmann G, et al. Importance of iron supply for erythropoietin therapy. Nephrology, Dialysis and Transplantation 1995; 10: 2070-2076

78. Sunder-Plassmann G, et al. Comparative look at intravenous iron agents: pharmacology, efficacy and safety of iron dextran, iron saccharate and ferric gluconate. Seminars in dialysis 1999; 12(4): 243-248

79. Sunder-Plassmann G, et al. Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrology, Dialysis and Transplantation 1996; 11: 1797-1802

80. Tryba M, et al. Epoetin alfa plus autologous blood donation in patients with a low hematocrit scheduled to undergo orthopedic surgery. Seminars in Hematology 1996; 33(2):22-26

81. Van Wyck D, et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trials. Journal of the American Society of Nephrology 1999; 10: 91A

82. Van Wyck D, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trials. American Journal of Kidney Diseases 2000; 36(1): 88-97

83. Van Zyl-Smit, et al. Intravenous iron sucrose on hemodialyisis - A multicentre clinical study. Kidney International 1999; 55(5): 2130

84. Vychtil A, et al. Iron status and iron supplementation in peritoneal dialysis patients. Kidney International 1999; 55(69): S71-S78

85. Yavuz M, et al. The intravenous iron therapy decreases the cost of recombinant human erythropoietin. Abstract from the XXXV Congress of the European Renal Association/ European Dialysis and Transplant Association, 6-9 June 1998, Rimini, Italy

86. Zimmerman R, et al. RHuEPO treatment of postpartum anemia. Journal of Perinatal Medicine 1995; 23: 111-117